Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa học: "A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects. | Guenzi et al. Radiation Oncology 2010 5 111 http www.ro-journal.eom content 5 1 111 RADIATION ONCOLOGY RESEARCH Open Access A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects 1Ỷ 1 Ỷ 1Ỷ 1 1 2 Marina Guenzi Stefano Vagge Ngwa Che Azinwi Alessia D Alonzo Liliana Belgioia Stefania Garelli Marco Gusinu2 Renzo Corvò1 2 3 Abstract Background Radiation therapy after lumpectomy is a standard part of breast conserving therapy for invasive breast carcinoma. The most frequently used schedule worldwide is 60 Gy in 30 fractions in 6 weeks a time commitment that sporadically may dissuade some otherwise eligible women from undertaking treatment. The purpose and primary endpoint of this perspective study is to evaluate feasibility and short-term late toxicity in a hypofractionated whole breast irradiation schedule. Methods Between February and October 2008 we treated 65 consecutive patients with operable invasive early-stage breast cancer with a hypofractionated schedule of external beam radiation therapy. All patients were assigned to 39 Gy in 13 fractions in 3 weeks to the whole breast plus a concomitant weekly boost dose to the lumpectomy cavity of 3 Gy in 3 fractions. Results All the patients had achieved a median follow up of 24 months range 21-29 months . At the end of treatment 52 presented grade 0 acute toxicity 39 had grade 1 and 9 had grade 2. At 6 months with all the patients assessed there were 34 case of grade 1 subacute toxicity and 6 of grade 2. At 12 months 43 and 3 of patients presented with clinical grade 1 and grade 2 fibrosis respectively and 5 presented grade 1 hyperpigmentation. The remaining patients were free of side effects. At 24 months with 56 assessed just 2 patients 3 showed grade 2 of late fibrosis. Conclusions The clinical results observed showed a reasonably good feasibility of the accelerated hypofractionated schedule in terms